A Review of Pharmacokinetic Drug–Drug Interactions with the Anthelmintic Medications Albendazole and Mebendazole

Clinical Pharmacokinetics

Volumn 54, Issue 4, 2015, Pages 371-383

  Pawluk, Shane Ashley ^a   Roels, Craig Allan ^b   Wilby, Kyle John ^a   Ensom, Mary H H ^b  

^a Qatar University ^*  (Qatar)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALBENDAZOLE; AZITHROMYCIN; CARBAMAZEPINE; CIMETIDINE; DEXAMETHASONE; DIETHYLCARBAMAZINE; IVERMECTIN; LEVAMISOLE; MEBENDAZOLE; PHENOBARBITAL; PHENYTOIN; PRAZIQUANTEL; RITONAVIR; ANTHELMINTIC AGENT;

ANTIMICROBIAL THERAPY; AREA UNDER THE CURVE; ELIMINATION HALF-LIFE; HUMAN; MAXIMUM PLASMA CONCENTRATION; META ANALYSIS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; ADULT; CHILD; COMBINATION DRUG THERAPY; DRUG INTERACTION; FEMALE; MALE; PRESCHOOL CHILD;

ADULT; ALBENDAZOLE; ANTHELMINTICS; CHILD; CHILD, PRESCHOOL; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MEBENDAZOLE;

EID: 84925499879     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-015-0243-9     Document Type: Review

References (48)

1. World Health Organization. WHO|Control of neglected tropical diseases is feasible. World Health Organization. Available at: http://www.who.int/neglected_diseases/en/. Accessed 25 Mar 2014.
2. Molyneux DH, Bradley M, Hoerauf A, Kyelem D, Taylor MJ. Mass drug treatment for lymphatic filariasis and onchocerciasis. Trends Parasitol. 2003;19:516–22.
3. Centers for Disease Control and Prevention. Neglected tropical diseases. Available at: http://www.cdc.gov/globalhealth/ntd/diseases/index.html. Accessed 28 Dec 2014.
4. GlaxoSmithKline. Zentel (Albendazole) product information. Product monograph version 3.0. 2011. Available at: http://www.gsk.com.au/resources.ashx/prescriptionmedicinesproductschilddataproinfo/1252/FileName/214005870BB4EF194E1B5C2A6F986051/Zentel_PI_-_clean.pdf. Accessed 18 Oct 2014.
5. Janssen. Vermox. Product monograph. 2013. Available at: http://www.janssen.ca/subcategory_docdownload?id=1747. Accessed 18 Oct 2014.
6. Dayan AD. Albendazole, mebendazole and praziquantel. Review of non-clinical toxicity and pharmacokinetics. Acta Tropica. 2003;86:141–59.
7. Li X-Q, Björkman A, Andersson TB, Gustafsson LL, Masimirembwa CM. Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol. 2003;59(5–6):429–42.
8. Chen K, Twu S, Chang H, Lin R. Outbreak of Stevens–Johnson syndrome/toxic epidermal necrolysis associate with mebendazole and metronidazole use among Filipino laborers in Taiwan. Am J Pub Health. 2003;93:489–92.
9. Schipper H, Koopmans R, Nagy J. Effect of dose increase or cimetidine co-administration on albendazole bioavailability. Am J Trop Med Hyg. 2000;63(5, 6):270–3.
10. Nagy J, Schipper HG, Koopmans RP, Butter JJ, van Boxtel CJ, Kager PA. Effect of grapefruit juice or cimetidine coadministration on albendazole bioavailability. Am J Trop Med Hyg. 2002;66:260–3.
11. Takayanagui OM, Lanchote VL, Marques MP, Bonato PS. Therapy for neurocysticercosis: pharmacokinetic interaction of albendazole sulfoxide with dexamethasone. Ther Drug Monit. 1997;19:51–5.
12. Jung H, Hurtado M, Tulio Medina M, Sanchez M, Sotelo J. Dexamethasone increases plasma levels of albendazole. J Neurol. 1990;237:279–80.
13. Corti N, Heck A, Rentsch K, Zingg W, Jetter A, Stieger B, et al. Effect of ritonavir on the pharmacokinetics of the benzimidazoles albendazole and mebendazole: an interaction study in healthy volunteers. Eur J Clin Pharmacol. 2009;65:999–1006.
14. Lanchote VL, Garcia FS, Dreossi SA, Takayanagui OM. Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. Ther Drug Monit. 2002;24:338–45.
15. Awadzi K, Edwards G, Duke BOL, Opoku NO, Attah SK, Addy ET, et al. The co-administration of ivermectin and albendazole: safety, pharmacokinetics and efficacy against Onchocerca volvulus. Ann Trop Med Parasitol. 2003;97:165–78.
16. Homeida M, Leahy W, Copeland S, Ali MM, Harron DW. Pharmacokinetic interaction between praziquantel and albendazole in Sudanese men. Ann Trop Med Parasitol. 1994;88:551–9.
17. Lima RM, Ferreira MAD, de Jesus Ponte Carvalho TM, Dumêt Fernandes BJ, Takayanagui OM, Garcia HH, et al. Albendazole–praziquantel interaction in healthy volunteers: kinetic disposition, metabolism and enantioselectivity. Br J Clin Pharmacol. 2011;71:528–35.
18. Pengsaa K, Na-Bangchang K, Limkittikul K, Kabkaew K, Lapphra K, Sirivichayakul C, et al. Pharmacokinetic investigation of albendazole and praziquantel in Thai children infected with Giardia intestinalis. Ann Trop Med Parasitol. 2004;98:349–57.
19. Na-Bangchang K, Kietinun S, Pawa KK, Hanpitakpong W, Na-Bangchang C, Lazdins J. Assessments of pharmacokinetic drug interactions and tolerability of albendazole, praziquantel and ivermectin combinations. Trans R Soc Trop Med Hyg. 2006;100:335–45.
20. Garcia HH, Lescano AG, Lanchote VL, Pretell EJ, Gonzales I, Bustos JA, et al. Pharmacokinetics of combined treatment with praziquantel and albendazole in neurocysticercosis. Br J Clin Pharmacol. 2011;72:77–84.
21. Shenoy RK, Suma TK, John A, Arun SR, Kumaraswami V, Fleckenstein LL, et al. The pharmacokinetics, safety and tolerability of the co-administration of diethylcarbamazine and albendazole. Ann Trop Med Parasit. 2002;96:603–14.
22. Amsden GW, Gregory TB, Michalak CA, Glue P, Knirsch CA. Pharmacokinetics of azithromycin and the combination of ivermectin and albendazole when administered alone and concurrently in healthy volunteers. Am J Trop Med Hyg. 2007;76:1153–7.
23. Awadzi K, Edwards G, Opoku NO, Ardrey AE, Favager S, Addy ET, et al. The safety, tolerability and pharmacokinetics of levamisole alone, levamisole plus ivermectin, and levamisole plus albendazole, and their efficacy against Onchocerca volvulus. Ann Trop Med Parasitol. 2004;98:595–614.
24. Luder PJ, Siffert B, Witassek F, Meister F, Bircher J. Treatment of hydatid disease with high oral doses of mebendazole. Eur J Clin Pharmacol. 1986;31:443–8.
25. Bekhti A, Pirotte J. Cimetidine increases serum mebendazole concentrations. Implications for treatment of hepatic hydatid cysts. Br J Clin Pharmacol. 1987;24:390–2.
26. Merino G, Molina A, García JL, Pulido MM, Prieto JG, Alvarez AI. Ginseng increases intestinal elimination of albendazole sulfoxide in the rat. Comp Biochem Physiol Part C Toxicol Pharmacol. 2003;136:9–15.
27. Merino G, Molina AJ, Garcia JL, Pulido MM, Prieto JG, Alvarez A. Intestinal elimination of albendazole sulfoxide: pharmacokinetic effects of inhibitors. Int J Pharm. 2003;263:123–32.
28. Atef M, El-Gendi AY, Amer AM, Abd El-Aty AM. Effect of three anthelmentics on disposition kinetics of florfenicol in goats. Food Chem Toxicol. 2010;48:3340–4.
29. El-Sooud K. Influence of albendazole on the disposition kinetics and milk antimicrobial equivalent activity of enrofloxacin in lactating goats. Pharmacol Res. 2003;48:389–95.
30. Virkel G, Lifschitz A, Sallovitz J, Inza G, Lanusse C. Effect of the ionophore antibiotic monensin on the ruminal biotransformation of benzimidazole anthelmintics. Vet J. 2004;167:265–71.
31. Alvarez L, Lifschitz A, Entrocasso C, Manazza J, Mottier L, Borda B, et al. Evalutaion of the interaction between ivermectin and albendazole following their combined use in lambs. J Vet Pharmacol Ther. 2008;31:230–9.
32. Merino G, Molina AJ, Garcia JL, Pulido MM, Prieto JG, Alvarez AI. Effect of clotrimazole on microsomal metabolism and pharmacokinetics of albendazole. J Pharm Pharmacol. 2003;55:757–64.
33. López-García ML, Torrado S, Martínez AR, Bolás F. Methimazole-mediated enhancement of albendazole oral bioavailability and anthelmintic effects against parenteral stages of Trichinella spiralis in mice: the influence of the dose-regime. Vet Parasitol. 1998;75:209–19.
34. Merino G, Alvarez A, Prieto J, Kim R. The anthelminthic agent albendazole does not interact with p-glycoprotein. Drug Metab Dispos. 2002;30(4):365–9.
35. Wen H, Zhang HW, Muhmut M, Zou PF, New RR, Craig PS. Initial observation on albendazole in combination with cimetidine for the treatment of human cystic echinococcosis. Ann Trop Med Parasitol. 1994;88:49–52.
36. Schneider D, Gannon R, Sweeney K, Shore E. Theophylline and antiparasitic drug interactions. Chest. 1990;97:84–7.
37. Adebayo G, Mabadeje A. Theophylline disposition: effects of cimetidine, mebendazole and albendazole. Aliment Pharmacol Ther. 1988;2:341–6.
38. Lange H, Eggers R, Bircher J. Increased systemic availability of albendazole when taken with a fatty meal. Eur J Clin Pharmacol. 1988;34:315–7.
39. Mares SS, Jung CH, López AT, González-Esquivel DF. Influence of a Mexican diet on the bioavailability of albendazole. Basic Clin Pharmacol Toxicol. 2005;97:122–4.
40. Jung H, Medina L, García L, Fuentes I, Moreno-Esparza R. Absorption studies of albendazole and some physicochemical properties of the drug and its metabolite albendazole sulphoxide. J Pharm Pharmacol. 1998;50:43–8.
41. Gottschall DW, Theodorides VJ, Wang R. The metabolism of benzimidazole anthelmintics. Parasitol Today. 1990;6:115–24.
42. Li X-Q, Björkman A, Andersson TB, Gustafsson LL, Masimirembwa CM. Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol. 2003;59:429–42.
43. Moroni P, Buronfosse T. Chiral sulfoxidation of albendazole by the flavin adenine dinucleotide-containing and cytochrome P450-dependent monooxygenases from rat liver microsomes. Drug Metab Dispos. 1995;23:160–5.
44. Lin JH, Lu AYH. Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet. 1998;35:361–90.
45. McCune JS, Hawke RL, Lecluyse EL. In vivo and in vitro induction of human cytochrome P450 3A4 by dexamethasone. Clin Pharmacol Ther. 2000;68:356–66.
46. Yeh RF, Gaver VE, Patterson KB, Rezk NL, Baxter-Meheux F, Blake MJ, et al. Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by phenotyping drug cocktail in healthy volunteers. J Acquir Immune Defic Syndr. 2006;42:52–60.
47. Lin JH, Lu AYH. Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet. 1998;35:361–90.
48. Riva R, Albani F, Contin M, Baruzzi A. Pharmacokinetic interactions between antiepileptic drugs. Clin Pharmacokinet. 1996;31:470–93.